Theravance Biopharma Inc (TBPH NASDAQ) stock market data APIs
$11.0955
0.03(0.3%)
as of July 3, 2025
Try our APIs with
free plan!
Theravance Biopharma Inc Financial Data Overview
Price chart is built with
Anychart
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Prev. Close
11.0955
Open
11.1303
High
11.3392
Low
10.908
52 wk Range
7.44-11.82
Market Cap
558 M
Shares Outstanding
50 001 K
Revenue
65 266 K
EPS
-0.1734
Beta
-0.079
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Theravance Biopharma Inc data using free add-ons & libraries
Get Theravance Biopharma Inc Fundamental Data
Theravance Biopharma Inc Fundamental data includes:
- Net Revenue: 65 266 K
- EBITDA: -43 972 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Theravance Biopharma Inc News
New
Theravance higher as China approves Viatris-partnered COPD therapy
[Wooden Approved Stamp] kemalbas Theravance Biopharma (NASDAQ:TBPH [https://seekingalpha.com/symbol/TBPH]) added ~7% in the premarket on Thursday after the company announced that China approved its V...
Theravance To Receive Milestone Payment From Viatris For Regulatory Approval Of YUPELRI In China
(RTTNews) - Theravance Biopharma, Inc. (TBPH) announced that Viatris Inc. has secured regulatory approval from China's National Medical Products Administration for YUPELRI inhalation solution, the fir...
China approves Theravance's YUPELRI for COPD treatment
DUBLIN - China’s National Medical Products Administration (NMPA) has approved YUPELRI (revefenacin) inhalation solution as the first once-daily nebulized long-acting muscarinic antagonist for mainte...
Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA
YUPELRI approved by China's NMPA as the first once-daily nebulized LAMA for maintenance treatment of COPD Approval triggers $7.5 million milestone payment from Viatris, with eligibility to receive fu...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
